USA Corporations Expand Pharma R&D Spending
There is a new wave of pharma R&D spending happening globally - and particularly when it comes to companies in the US. While there is now limited scope for investing in R&D relating to generic medicines, due to the hot competition around these products, opportunities exist in many other areas, from specialist medicines to biologics. There are many US corporations that have the resources and facilities to focus on this in-house but others don't, which is why we are beginning...
View full press release